ArticleClinicoEconomics and outcomes research : CEOR2021

Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy.

Gianni Ghetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.